Fritextsökning
Innehållstyper
-
Computed tomography in measurement of medical plastic products
Watch the recordings from ZEISS Quality Innovation Summit.
-
The new Astra Zeneca CEO: “An incredibly exciting phase”
Almost 27 years have passed since Per Alfredsson from Södertälje stepped into Astra Zeneca as a newly hired engineer. After countless different roles, including...
-
KI’s new President: “We need to work closer together”
A closer link between research and education and a stronger “we-feeling” are aims that Annika Östman Wernerson sets out to achieve as the new President of Karol...
-
Saving lives worldwide with low-cost molecular diagnostics
High throughput testing for many upper respiratory tract pathogens thanks to automation technology
-
Neanderthal gene variants may cause Viking disease
A new study suggests that the so-called Viking disease, which affects the hand function in many older people, may be linked to gene variants inherited from Neanderthals.
-
ZEISS Quality Innovation Days
The leading digital event from April 15-19, 2024.
-
How Volume EM Advances Life Science Research
Free webinar series.
-
Studie: Aspirin kan halvera risken för återfall vid tarmcancer
En låg dos av aspirin kan dramatiskt minska återfallsrisken vid tjock- och ändtarmscancer, enligt en ny nordisk studie. Effekten var särskilt tydlig hos patient...
-
ZEISS Insights: Measurement of bone plates and screws
Get free access to technical paper.
-
The fast route to a safe insulin pen
Diabetes is on the rise worldwide with around ten million people developing the disease every year. Demand for insulin pens allowing patients to self-medicate i...
-
A new special edition and a new event in Copenhagen – This is happening at Life Science Sweden 2024
The new year brings new features for the readers of Life Science Sweden.
-
Bio-Works
-
Pila Pharma tar in 20 miljoner kronor – inleder ”dedikerat fetmaspår”
Malmöbolaget Pila Pharma utvecklar ett nytt, oralt läkemedel för behandling av typ 2-diabetes. Ett nytt kapitaltillskott ska användas för att initiera studier o...
-
Abbvie förvärvar lovande projekt inom psykisk ohälsa
Abbvie köper ett läkemedelsprogram inom mental hälsa i en miljardaffär som ser lite annorlunda än vad som tidigare uppgetts.
-
Ingrid Lönnstedt: What does the p-value mean?
The smaller the better, and preferably smaller than 0.05. A p-value smaller than 5% means that the treatment effect is statistically significant at 5% significa...
-
Marie Gårdmark: “What to expect from Trump’s second term?”
One may complain about the complex multinational system in EU, but it gives us some predictability that cannot be easily overturned by different member states p...
-
Standardisation in automation
B. Braun Melsungen had a great idea and implemented it throughout the plant. Production for infusion solutions was to be largely standardised. B. Braun hoped th...
-
Eternal Rye – Improving Plant Breeding Methods
User story from Martin Luther University Halle.
-
List: The coolest names in biotech
Hairy beasts, volcanic material and space strolling stand out on a US list of the best biotech company names, and on a list of the coolest names for pharmaceuti...
-
Business Sweden: “Companies have a lot to offer in data-driven precision medicine”
Data-driven precision medicine can potentially solve major healthcare problems, states Business Sweden in a new report on the subject.
-
How to optimise your liquid handling results
In dispensing or pipetting applications in laboratory automation, it is important to obtain reliable results, which are analysed by calculating the accuracy and...
-
Automated opening and closing of sample vials
From technical requirements to a suitable solution
-
AZ gets approval for drug targeting rare disease – it may reduce cortisone dependence
AstraZeneca’s drug Fasenra gets an expanded indication in the EU and is now approved as a treatment for the rare autoimmune disease known as Churg-Strauss syndrome.
-
A surprising discovery about the immune system in cases of cancer
Professor Göran Jönsson is trying to understand why some patients benefit from immunotherapies while others don’t. A couple of years ago, he made a surprising d...